106.30 <%= Resources.Global.txtUp %>
Updated 23/05/2019
Change % 0.85% Stock price increasing
Change 0.90 Stock price increasing
Volume 157,886
High 107.10
Low 105.40
Open 106.00
ISIN BE0003818359
Prev close 105.40
# of shares 54.61M
Market cap 5,805.54M EUR

Market closed
Market is closed, opens at 08:00
Price development Latest 1 week 1 month 3 months 6 months 1 year
  106.30 4.7% Stock price increasing 5.7% Stock price increasing 24.9% Stock price increasing 20.7% Stock price increasing 23.0% Stock price increasing
Powered by TradingView

News about Galapagos

  • English
  • Regulatory news

Company profile

Galapagos NV is a clinical-stage biotechnology company, involved in the discovery and development of small-molecule medicines. The company's product candidate portfolio includes Filgotinib, a JAK1 inhibitor to treat rheumatoid arthritis, Crohn's disease, and ulcerative colitis; novel therapies in cystic fibrosis (a chronic disease that affects the lungs and digestive system); GLPG1690, a selective autotaxin inhibitor with potential application in idiopathic pulmonary disease; GLPG1972 to treat osteoarthritis; and MOR106 to treat atopic dermatitis.

Copyright Berlingske Media 2019  Cookie- and Privacy policy  |  Cookies  |   General terms of trade  |   Terms of use and IP rights
Quote information is delivered by Morningstar.
Data is delayed 15-20 minutes according to the distribution agreements set by the different exchanges.
26 May 2019 14:52:07
(UTC+00:00) Dublin, Edinburgh, Lisbon, London
Version: LiveBranchBuild_20190514.2 - EUROWEB1 - 2019-05-26 15:52:07 - 2019-05-26 14:52:07 - 1000 - Website: OKAY